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ABSTRACT
 
The purpose of this research study is to develop a 
novel, simple, precise, accurate and economical 
method for determination of Apixaban API isomers. 
This chromatographic method was developed on 
chiralpak IA column(250 x 4.6 x 5µm) with isocritic 
technique. The detection of impurities was observed 
at wavelength 290nm. This analytical method was 
validated and regression analysis showed R value 
(correlation coefficient) > 0.999 for Apixaban and its 
isomeric impurities. A solution of Apixaban in 
dichloromethane was found stable up to 48 hrs. The 
degradation study was done within the given 
guidelines prescribed by ICH. The method is 
validated for linearity, accuracy and precision. 
 
Keywords: Apixaban, chiralpak IA column, isocritic, 
NP-HPLC, validation  
 
INTRODUCTION 
Apixaban is chemically known as 1-(4-
methoxyphenyl)-7-oxo-6-[4-(2-
oxopiperidin-1-yl)phenyl]-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-
carboxamide is a Anti -coagulant drug, a 
direct inhibitor of factor X, also used in the 
prevention of venous thrombo embolism. 
Apixaban is recommended by the National 
Institute for Health and Clinical 
Excellence for the prevention of stroke and 
systemic embolism in people with non-
valvular atrial fibrillation and at least one 
of the following risk factors: prior stroke 
or transient ischemic attack, age 75 years 
or older, diabetes mellitus, or symptomatic 
heart failure [1] 
OBJECTIVES OF THE STUDY 
The literature survey reveals that few 
analytical methods have been reported 
for Apixaban and its related compounds 
including spectroscopic methods, high 
performance liquid chromatography 
(HPLC) methods. Our objective is to 
develop and validate new NP-HPLC 
method for determination of Apixaban 
and its isomer [2]. The proposed NP-
HPLC method utilizes economical 
solvent system having advantage like 
better retention time, peak sharp and 
symmetric nature. The method is 
validated according to ICH Guidelines.
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INSTRUMENTATION 
Waters, Alliance 2695 series HPLC 
system comprising a quaternary pump, an 
auto-sampler, a thermostat column 
compartment, a solvent cabinet with gasser 
along with photo diode array (PDA) 2998 
and ultraviolet (UV) 2487 detectors were 
used for separation and detection. Data 
acquisition and calculations were carried 
out using Waters Empower3 software 
(Milford). Sartorius(Germany) analytical 
balance was used for weighing material. 
MATERIALS AND REAGENT 
Apixaban sample, working standard and 
its related substances working standard 
were received from Analytical Research 
and Development department of Indoco 
Research Centre (Navi Mumbai). HPLC 
grade n- Hexane, Toluene, Methanol, 
Ethanol and Dichloromethane were 
purchased from Merck (India).
 
Table 1: Chemical name of Apixaban and its isomer. 
Sr No. Component Name Chemical Name Structure 
1 Apixaban 
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-
oxopiperidin-1-yl)phenyl]-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-
c]pyridine-3-carboxamide. 
N
N
N
N
O
O
O
NH2
OCH3
 
2 
Apixaban meta 
isomer 
1-(2-methoxyphenyl)-7-oxo-6-(4-(2-
oxopoperidine-1-yl)phenyl)-4,5,6,7-
tetrahydro-1H-pyrazole(3,4-
c)pyridine-3-carboxamide 
 
N
N
N
O
NH2O
N
O
OCH3
 
3 
Apixaban ortho 
isomer 
1-(3-methoxyphenyl)-7-oxo-6-(4-(2-
oxopoperidine-1-yl)phenyl)-4,5,6,7-
tetrahydro-1H-pyrazole(3,4-
c)pyridine-3-carboxamide. 
N
N
N
O
NH2O
N
O
OCH3
 
 
CHROMATOGRAPHIC CONDITION 
AND MEASUREMENT PROCEDURE 
Mobile Phase 
Mix 65 volume of n-Hexane, 15 volume of 
Toluene, 10 volume of Methanol and 10 
volume of Ethanol and degas by sonication 
for 2 mins [3-6]. 
Diluent 
Methanol. 
 
Preparation of Blank 
Transfer 5 ml Dichloromethane into 10 ml 
volumetric flask and make up with diluent.
Table 2: Chromatographic conditions. 
Column Chiralapk IA (250mm x 4.6 mm, 5 µm) 
Column Temperature 25°C ± 2°C 
Flow Rate 1.0 mL/min 
Injection Volume 30 L 
Detector Wavelength 290 nm  
Run Time 60 minutes 
Retention Time Apixaban (APX) about 32 minutes, 
Needle wash Dichloromethane 
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Preparation of Solutions 
System Suitability Solution 
Transfer about 5 mg of Apixaban working 
standard, Apixaban ortho impurity and 
Apixaban meta impurity into 10 mL 
volumetric flask, add 5 ml 
dichloromethane and dissolve in and make 
upto the mark with diluent [7]. 
 
Reference Solution (a) 
Transfer about 60 mg of Apixaban 
working standard into 10 mL volumetric 
flask, dissolve in about 5 mL of 
dichloromethane and make upto the mark 
with diluent.  Transfer 1 mL of above 
solution to 100 mL volumetric flask and 
make upto the mark with diluent. Further 
transfer 1 mL of above solution into 10 
mL volumetric flask and make upto the 
mark with diluent [8]. 
 
Test Solution 
Transfer about 60 mg of Apixaban sample 
into 10 mL volumetric flask, dissolve in 
about 5 mL of dichloromethane and make 
upto the mark with diluent.
 
Table 3: Injection sequence. 
Sr. No. Description No. of Injections 
1 Blank 1 
2 System suitability solution 1 
3 Blank 1 
4 Reference solution (a) 5 
5 Test solution 2 
 
Procedure 
Equilibrate the HPLC system with the 
initial composition until a steady baseline 
is obtained. Inject Blank, System 
suitability solution and reference solution 
(a). Ensure that all the system suitability 
parameters meet the requirements. Inject 
test solution as per injection sequence and 
record the chromatograms. Make blank 
correction if necessary [9]. 
 
Table 4: Peak name with retention time and relative response factor. 
Sr. No. Peak Name Relative Retention Time Relative Retention Factor 
1 Apixaban 1.00 1.00 
2 Ortho impurity 0.58 0.55 
3 Meta impurity 0.90 0.80 
 
SYSTEM SUITABILITY 
Acceptance Criteria 
Resolution 
The resolution between the peaks due to 
meta impurity and Apixaban in the 
chromatograms obtained with system 
suitability solution should not be less than 
1.5. 
 
Percent RSD 
The percent relative standard deviation of 
three replicates for the peak due to 
Apixaban in the chromatograms obtained 
with reference solution (a) should not be 
more than 5.0. 
 
Calculation 
Calculate impurity content by formula 
given below:  
                                                                     
                                 AI x WS x 1 x 1 x 1 
% Ortho/Meta impurity =        x P 
                        AR x WT x 100 x 10 x RRF 
 
Where, 
AI = Average peak area for respective 
impurity in test solution. 
AR = Average peak area of Apixaban in 
reference solution (a). 
WS = Weight in mg of Apixaban working 
standard taken for reference solution (a) 
preparation [10]. 
  
23 Page 20-27 © MAT Journals. All Rights Reserved 
 
Research & Review: Drugs and Drugs Development  
Volume 2, Issue 1 
 
WT = Weight in mg of Apixaban sample 
taken for test solution preparation. 
P = Potency of Apixaban working standard 
(%). 
 
Analytical Method Validation 
The developed method is subjected to 
analytical method validation, which is 
conducted according to International 
Council for harmonization (ICH) 
guidelines. The parameters with which 
analytical method is validated are 
specificity, limit of detection and limit 
of quantification, linearity, accuracy, 
precision [11]. 
 
Specificity 
Specificity is capability of the method to 
measure the analyte response in presence 
of impurities. The typical chromatograms 
of blank Solution, System suitability 
solution, Reference Solution (a), and 
Impurities Spike Solution are given from 
Fig. 1 to 4 respectively. The results 
indicate that all impurities are well 
separated under the current 
chromatographic conditions. There was no 
interference of peak from blank solution 
and samples solution within retention time 
of impurities obtained. Peak purity for 
Apixaban and its impurities were passing. 
For retention time of each impurity and its 
peak purity refer Table 5 [12]. 
 
Figure 1: Blank. 
 
 
Figure 2: System suitability solution. 
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Figure 3: Reference solution (a). 
 
 
Figure 4: Impurities spiked in sample. 
 
Table 5: Peak purity and RT Ratio for Apixaban and its impurities. 
Sr. No. Peak name RT RT Ratio Purity Angle Purity Threshold 
1 Apixaban 32.0 1.00 0.22 1.18 
2 Ortho impurity 18.56 0.58 0.19 1.17 
3 Meta impurity 28.8 0.90 0.22 1.16 
 
Limit of Detection and Limit of 
Quantification 
Series of standard solution of Apixaban 
and its impurities were prepared and 
injected in concentration ranging from 
50% to 500%. Limit of detection (LOD) 
and Limit of quantification(LOQ) was 
calculated based on residual standard 
deviation of regression line and slope. 
Both calculated LOD and LOQ were 
well within limit. The LOQ is below 
0.057% for impurities and Apixaban 
API. For details of LOQ and LOD refer 
Table.
 
Table 6: LOD and LOQ. 
Sr. No. Name of Impurity LOD(%) LOQ(%) 
1 Apixaban 0.019 0.057 
2 Ortho impurity 0.018 0.055 
3 Meta impurity 0.011 0.032 
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Linearity 
Series of linearity solution of Apixaban 
and its impurities were prepared from 50% 
to 500% of test concentration. Linearity 
curves were drawn by plotting the peak 
areas of Apixaban and its impurities 
against its corresponding concentration of 
linearity solution. Observed regression 
coefficient was greater than 0.998 and % 
y-intercept was less than 5.0%.
 
Table 7: Linearity table and its R
2
 values. 
Apixaban 
 
Slope 2265608.63 
Intercept 19532.23 
Co-relation Coefficient (R
2
) 0.9993 
% Y-Intercept 2.77 
 
Meta Impurity 
 
 
Slope 1757553.28 
Intercept -17795.47 
Co-relation Coefficient (R2) 0.9998 
% Y-Intercept -3.37 
Ortho Impurity 
 
 
 
Slope 1239296.68 
Intercept -7260.83 
Co-relation Coefficient (R
2
) 0.9994 
% Y-Intercept -4.02 
 
Accuracy 
Accuracy of method is calculated and 
established by carrying out recovery 
studies of impurities. The test solution was 
spiked with impurities solution at specific 
limit level concentration 100%, 150%, 
300%. Each spiked test solution was 
analyzed for recovery study of impurities. 
Recovery established is between 100% to 
105%.
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Table 8: Recovery of impurities at 100%. 
Sr.No. Imp Name 
Area of 0.10% 
Level 
Theoretical imp 
Added % 
% of IMP 
Observed 
% of 
Recovery 
1 Ortho Impurity 103945 0.09 0.09 103.15 
2 Meta Impurity 147724 0.09 0.09 100.78 
 
Table 9: Recovery of impurities at 150%. 
Sr.No. IMP Name Area of 0.15% 
Level 
Theoretical imp 
Added % 
% of IMP 
Observed 
% of 
Recovery 
1 Ortho Impurity 160337 0.13 0.14 104.56 
2 Meta Impurity 226362 0.13 0.14 101.49 
 
Table 10: Recovery of impurities at 300%. 
Sr.No. IMP Name Area of 0.30% 
Level 
Theoretical imp 
Added % 
% of IMP 
Observed 
% of 
Recovery 
1 Ortho Impurity 319004 0.27 0.28 104.88 
2 Meta Impurity 444756 0.27 0.27 100.52 
 
Precision 
System precision was carried out by 
analyzing six injections of reference 
solution (a) of Apixaban API at limit level 
concentration. Relative standard deviation 
for peak area of Apixaban was calculated 
and found to be 0.33%. 
 
Robustness 
Robustness was studied by making small 
but deliberate changes in optimized 
method conditions and evaluating the 
effect on resolution between ortho 
impurity, meta impurity and Apixaban. 
The mobile phase flow rate was changed 
by +0.1 units from 1.0 to 0.9 and 1.1 
ml/min.  
 
Solution Stability 
The solution stability of Apixaban and its 
impurities in related substances method 
was evaluated by leaving a spiked solution 
in tightly capped volumetric flask at room 
temperature for 48 hrs and analysis of all 
its impurities content was done at interval 
of 12 hrs. 
 
RESULT AND DISCUSSION 
Since, most of the impurities are non-polar 
in nature, various chiral columns were 
screened. The parameters like tailing 
factor and theoretical plates were recorded 
during the study. From obtained data 
Chiralpak IA (250 x 4.6 x 5µm) was found 
suitable for analysis. 
 
All impurities were prepared at 100 ppm 
and their UV-visible spectra was acquired. 
The Apixaban and all its impurities has 
good and satisfactory response at 290nm. 
Hence detection at 290nm was selected for 
method-development. 
 
Retention time were confirmed by 
injecting working standards of Apixaban, 
Meta and ortho impurities. For system 
suitability, the resolution between 
Apixaban and Meta imp should be not less 
then 1.5. Relative Standard Deviation for 
five replicate injections peak due to 
Apixaban should not be more then 5%.  
 
CONCLUSION 
The analytical method validation for 
Apixaban by normal Phase HPLC was 
carried out by performing the parameters 
such as specificity, limit of detection and 
limit of quantification, linearity, accuracy, 
precision, robustness and solution stability. 
All the data has been compiled and found 
to be satisfactory. Hence, method 
developed for normal Phase HPLC can be 
suitably used for analysis of Apixaban 
isomer in pharmaceutic industries. 
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